GLP1R and optic papillitis: The rapid onset of effect observed in our study (maximum benefit at 3 months) supports findings by Krajnc et al., who reported comparable improvements in papilledema using other GLP‐1 RAs, suggesting a class‐wide benefit in IIH.5